Mark G Foletta - Net Worth and Insider Trading
Mark G Foletta Net Worth
The estimated net worth of Mark G Foletta is at least $5 Million dollars as of 2024-11-13. Mark G Foletta is the Director of DexCom Inc and owns about 59,371 shares of DexCom Inc (DXCM) stock worth over $4 Million. Mark G Foletta is the Director of AMN Healthcare Services Inc and owns about 8,573 shares of AMN Healthcare Services Inc (AMN) stock worth over $223,670. Mark G Foletta is also the EVP & CFO of Tocagen Inc and owns about 1,003 shares of Tocagen Inc (TOCA) stock worth over $18,957. Besides these, Mark G Foletta also holds Regulus Therapeutics Inc (RGLS) . Details can be seen in Mark G Foletta's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark G Foletta has not made any transactions after 2024-06-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark G Foletta
Mark G Foletta Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark G Foletta owns 6 companies in total, including DexCom Inc (DXCM) , Enanta Pharmaceuticals Inc (ENTA) , and AMN Healthcare Services Inc (AMN) among others .
Click here to see the complete history of Mark G Foletta’s form 4 insider trades.
Insider Ownership Summary of Mark G Foletta
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| DXCM | DexCom Inc | 2024-06-18 | director |
| ENTA | Enanta Pharmaceuticals Inc | 2022-03-03 | director |
| AMN | AMN Healthcare Services Inc | 2024-02-29 | director |
 | | 2017-04-12 | EVP & Chief Financial Officer |
| | 2015-08-13 | director |
| | 2015-08-18 | Interim CFO |
Mark G Foletta Latest Holdings Summary
Mark G Foletta currently owns a total of 4 stocks. Among these stocks, Mark G Foletta owns 59,371 shares of DexCom Inc (DXCM) as of June 18, 2024, with a value of $4 Million and a weighting of 94.79%. Mark G Foletta owns 8,573 shares of AMN Healthcare Services Inc (AMN) as of February 29, 2024, with a value of $223,670 and a weighting of 4.8%. Mark G Foletta also owns 1,003 shares of Tocagen Inc (TOCA) as of May 28, 2019, with a value of $18,957 and a weighting of 0.41%. The other 1 stocks Regulus Therapeutics Inc (RGLS) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Mark G Foletta
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| DXCM | DexCom Inc | 2024-06-18 | 59,371 | 74.34 | 4,413,640 |
| AMN | AMN Healthcare Services Inc | 2024-02-29 | 8,573 | 26.09 | 223,670 |
| TOCA | Tocagen Inc | 2019-05-28 | 1,003 | 18.90 | 18,957 |
| RGLS | Regulus Therapeutics Inc | 2015-08-13 | 83 | 1.56 | 129 |
Holding Weightings of Mark G Foletta
Mark G Foletta Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark G Foletta has made a total of 11 transactions in DexCom Inc (DXCM) over the past 5 years, including 0 buys and 11 sells. The most-recent trade in DexCom Inc is the sale of 6,000 shares on June 18, 2024, which brought Mark G Foletta around $702,000.
According to the SEC Form 4 filings, Mark G Foletta has made a total of 4 transactions in AMN Healthcare Services Inc (AMN) over the past 5 years, including 1 buys and 3 sells. The most-recent trade in AMN Healthcare Services Inc is the acquisition of 500 shares on February 29, 2024, which cost Mark G Foletta around $28,450.
According to the SEC Form 4 filings, Mark G Foletta has made a total of 0 transactions in Tocagen Inc (TOCA) over the past 5 years. The most-recent trade in Tocagen Inc is the acquisition of 333 shares on May 28, 2019, which cost Mark G Foletta around $21,500.
More details on Mark G Foletta's insider transactions can be found in the Insider Trading History of Mark G Foletta table.Insider Trading History of Mark G Foletta
- 1
Mark G Foletta Trading Performance
GuruFocus tracks the stock performance after each of Mark G Foletta's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark G Foletta is -4.11%. GuruFocus also compares Mark G Foletta's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark G Foletta within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark G Foletta's insider trading performs compared to the benchmark.
Performance of Mark G Foletta
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 24.79 | | | | | |
| Relative Return to S&P 500(%) | 23.78 | | | | | |
Mark G Foletta Ownership Network
Ownership Network List of Mark G Foletta
Ownership Network Relation of Mark G Foletta
Mark G Foletta Owned Company Details
What does DexCom Inc do?
Who are the key executives at DexCom Inc?
Mark G Foletta is the director of DexCom Inc. Other key executives at DexCom Inc include Chief Human Resources Officer Sadie Stern , SVP & Research & Development Jacob Steven Leach , and SVP & Finance & CAO Jereme M Sylvain .
DexCom Inc (DXCM) Insider Trades Summary
Over the past 18 months, Mark G Foletta made no insider transaction in DexCom Inc (DXCM). Other recent insider transactions involving DexCom Inc (DXCM) include a net sale of 30,958 shares made by Sadie Stern , a net sale of 18,313 shares made by Micheal Jon Brown , and a net sale of 7,911 shares made by Steven Robert Pacelli .
In summary, during the past 3 months, insiders sold 3,604 shares of DexCom Inc (DXCM) in total and bought 0 shares, with a net sale of 3,604 shares. During the past 18 months, 316,886 shares of DexCom Inc (DXCM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 316,886 shares.
DexCom Inc (DXCM)'s detailed insider trading history can be found in Insider Trading Tracker table.
DexCom Inc Insider Transactions
Mark G Foletta Mailing Address
Above is the net worth, insider trading, and ownership report for Mark G Foletta. You might contact Mark G Foletta via mailing address: Amylin Pharmaceuticals Inc, 9360 Towne Centre Dr, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
